| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GAGE5 |
| Uniprot No | Q13069 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-117aa |
| 氨基酸序列 | MSWRGRSTYYWPRPRRYVQPPEVIGPMRPEQFSDEVEPATPEEGEPATQRQDPAAAQEGEDEGASAGQGPKPEADSQEQGHPQTGCECEDGPDGQEMDPPNPEEVKTPEEGEKQSQC |
| 预测分子量 | 39.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于GAGE5重组蛋白的模拟参考文献示例(文献为假设性描述，供参考)：
---
1. **文献名称**：*Expression and Purification of Recombinant GAGE5 Protein in Escherichia coli*
**作者**：Zhang Y, et al.
**摘要**：本研究报道了在大肠杆菌系统中高效表达GAGE5重组蛋白的方法，通过优化密码子和纯化步骤获得高纯度蛋白，并验证其抗原性，为后续癌症免疫研究奠定基础。
2. **文献名称**：*GAGE5 Recombinant Protein Induces Cytotoxic T-Cell Responses in Melanoma Models*
**作者**：Smith JL, et al.
**摘要**：利用哺乳动物细胞表达系统制备GAGE5重组蛋白，证实其可激活患者来源的T细胞，特异性杀伤表达GAGE5的黑色素瘤细胞，提示其作为肿瘤疫苗的潜力。
3. **文献名称**：*Structural Analysis of GAGE5 Recombinant Protein by X-ray Crystallography*
**作者**：Kim H, et al.
**摘要**：通过重组表达和晶体学解析GAGE5的三维结构，揭示其与HLA分子结合的关键表位，为设计靶向GAGE5的免疫疗法提供结构基础。
4. **文献名称**：*GAGE5 Recombinant Protein as a Serum Biomarker in Hepatocellular Carcinoma*
**作者**：Wang X, et al.
**摘要**：开发基于GAGE5重组蛋白的ELISA检测方法，发现其在肝癌患者血清中特异性升高，提示其作为诊断或预后标志物的可能性。
---
**注意**：以上文献为模拟内容，实际引用需查询真实数据库(如PubMed)。如需真实文献，建议检索关键词 "GAGE5 recombinant protein" 并筛选近年研究。
The GAGE5 protein, part of the GAGE (G antigen) family, is a cancer-testis antigen (CTA) predominantly expressed in germline cells and reactivated in various malignancies. Encoded by the *GAGE5* gene located on chromosome Xp11.4. it shares structural homology with other GAGE family members, characterized by conserved PRAME-like domains implicated in protein-protein interactions. Under normal physiological conditions, GAGE5 expression is restricted to the testes, but epigenetic dysregulation in cancer leads to its aberrant expression in tumors such as melanoma, lung, and ovarian cancers. This ectopic expression is associated with tumor progression, immune evasion, and poor prognosis, likely due to its role in modulating apoptosis, cell cycle regulation, and interaction with pathways like p53.
Recombinant GAGE5 protein is produced using heterologous expression systems (e.g., *E. coli* or mammalian cells) to enable functional and clinical studies. Its purification often involves affinity tags (e.g., His-tag) and chromatographic techniques, yielding high-purity protein for applications in cancer research. Recombinant GAGE5 serves as a critical tool for investigating its oncogenic mechanisms, including its potential as a biomarker or therapeutic target. It is also utilized in developing immunotherapies, such as peptide vaccines or CAR-T cells, leveraging its tumor-specific expression to elicit immune responses against cancer cells. Additionally, the protein aids in generating antibodies for diagnostic assays, enhancing early detection and monitoring of GAGE5-positive cancers. Despite its promise, challenges remain in understanding its precise molecular functions and overcoming immune tolerance in therapeutic contexts. Ongoing studies aim to unravel its post-translational modifications (e.g., phosphorylation) and interactions with intracellular partners, which could unlock novel strategies for precision oncology.
×
